BNC 210

Drug Profile

BNC 210

Alternative Names: BNC210; IW 2143

Latest Information Update: 18 Oct 2016

Price : $50

At a glance

  • Originator Bionomics
  • Class Antidepressants; Anxiolytics; Small molecules
  • Mechanism of Action Adenosine A3 receptor modulators; Alpha7 nicotinic acetylcholine receptor antagonists; Neurokinin 2 receptor modulators; Phospholipase C modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Anxiety disorders; Post-traumatic stress disorders
  • No development reported Depressive disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Anxiety-disorders(In volunteers) in France (PO, Suspension)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Depressive disorders in Australia (PO, Suspension)
  • 01 Jun 2016 Phase-II clinical trials in Post-traumatic stress disorder in Australia (PO) (NCT02933606)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top